Yellow fever vaccine-associated adverse events following extensive immunization in Argentina
| Autor: | Silvia Bentancourt, Cintia Fabbri, Cristián Biscayart, Máximo Diosque, María Alejandra Morales, Angela Gentile, Clara Digilio, Daniel Stecher, Delia Enria, Maria Eugenia Perez Carrega, Salvador García Jimenez, Tomás Orduna, Luis Pedro Flynn, Carla Vizzotti, Laura Bugna, María Andrea Uboldi, Gabriel Pirán Arce, Sandra Sagradini |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Argentina Yellow fever vaccine Young Adult Environmental protection Environmental health parasitic diseases Epidemiology medicine Adverse Drug Reaction Reporting Systems Humans Young adult Medical prescription Child Adverse effect Aged Aged 80 and over General Veterinary General Immunology and Microbiology business.industry Vaccination Yellow Fever Vaccine Public Health Environmental and Occupational Health Infant Outbreak Middle Aged Infectious Diseases Immunization Child Preschool Molecular Medicine Female business medicine.drug |
| Zdroj: | Vaccine. 32:1266-1272 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2014.01.015 |
| Popis: | As a consequence of YF outbreaks that hit Brazil, Argentina, and Paraguay in 2008-2009, a significant demand for YF vaccination was subsequently observed in Argentina, a country where the usual vaccine recommendations are restricted to provinces that border Brazil, Paraguay, and Bolivia. The goal of this paper is to describe the adverse events following immunization (AEFI) against YF in Argentina during the outbreak in the northeastern province of Misiones, which occurred from January 2008 to January 2009. During this time, a total of nine cases were reported, almost two million doses of vaccine were administered, and a total of 165 AEFI were reported from different provinces. Case study analyses were performed using two AEFI classifications. Forty-nine events were classified as related to the YF vaccine (24 serious and 1 fatal case), and 12 events were classified as inconclusive. As the use of the YF 17D vaccine can be a challenge to health systems of countries with different endemicity patterns, a careful clinical and epidemiological evaluation should be performed before its prescription to minimize serious adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect